Navigation Links
Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial

per protocol clinical cure rate compared to Biaxin(R) in CAP (cethromycin 91.5% (205/224) compared to Biaxin(R) 95.9% (212/221) [-9.1, +0.3], p=0.0775). Cethromycin's achievement of a 91.5% clinical cure rate is consistent with its Phase 2 clinical trial results at the same 300 mg once-daily dose for CAP. The comparator drug, Biaxin(R), achieved a cure rate higher than the historical rate observed in any reported Biaxin(R) CAP clinical trials to date.

Cethromycin also achieved positive safety results in the study. Cethromycin demonstrated an improved safety profile when compared with the results seen in its previous clinical trials. Additionally, the incidence of adverse events was not statistically different between cethromycin and Biaxin(R). The most common adverse events reported in patients receiving cethromycin were mild-to-moderate diarrhea (cethromycin 5.0%, Biaxin(R) 4.6%), headache (cethromycin 3.1%, Biaxin(R) 6.5%), nausea (cethromycin 2.7%, Biaxin(R) 3.8%), vomiting (cethromycin 2.7%, Biaxin(R) 1.5%), abdominal pain (cethromycin 1.5%, Biaxin(R) 3.1%) and taste disturbance (cethromycin 11.1%, Biaxin(R) 6.2%). No drug-related serious adverse events were observed in any study subject. Liver function tests and electrocardiogram monitoring demonstrated no significant differences between subjects receiving cethromycin and subjects receiving Biaxin(R), consistent with the hepatic and cardiac side effect profile reported in cethromycin's previous clinical trials.

Cethromycin is not approved as a treatment for CAP, and data from this analysis have not been reviewed by the FDA. No further details of the clinical study will be available until all data analyses are complete and results are presented in a public, scientific forum.

Program Design

The Phase 3 CAP clinical trial program is comprised of two randomized, well controlled, double-blind, multi-center, multi-national, comparator trials designed to assess the safety and effectiveness
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
2. Cethromycin Shown Effective Against Anthrax in Study
3. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
4. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
7. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
8. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
9. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
11. ENDEAVOR IV Clinical Trial Meets Primary Endpoint

Post Your Comments:
(Date:11/25/2009)..., NEW YORK, Nov. 25 Reportlinker...s available in its catalogue: ,, Intranasal Dr...tp://www.reportlinker.com/p0164267/Intranasal-Drug... The US intranasal drug delivery market is witness...the delivery of conventional local therapeutic dru...
(Date:11/25/2009)...NTAIN VIEW, Calif., Nov. 25 Chem...clinical data from the Company,s PROTECT-1 (the Pr...ohn,s disease Trial) of Traficet-EN(TM) (CCX282-B)...se demonstrated clinical efficacy with a favorable...strated evidence of clinical efficacy in the reduc...
(Date:11/24/2009)...VINE, Calif., Nov. 24 En...ally invasive treatments for aortic disorders, ann...r discontinue all proceedings in, the patent infri... by Cook, Inc. The motion was filed in the United..., Endologix has requested that the stay remain ...
Breaking Medicine Technology:Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR NCI EORTC MEETING 14904 1YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR NCI EORTC MEETING 14904 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR NCI EORTC MEETING 14904 3BeamOne LLC to Add New Ebeam Sterilization Service Center 6384 1BeamOne LLC to Add New Ebeam Sterilization Service Center 6384 2Residential design for persons with neurological disability 61642 1Residential design for persons with neurological disability 61642 2Residential design for persons with neurological disability 61642 3
...es,Pharmaceuticals, Inc., (Nasdaq: ALSE ), announ...n the initial stage of the ALTROPANE(R) Parkinson,...cal trial program. This,subject was enrolled at th...er the direction of Principal Investigator Dr. Ray...ment of Neurology., ALTROPANE is a diagnostic mol...
...(TM) shows lifesaving potential -, - HGS on trac...ockpile beginning in 2008...s, Inc. (Nasdaq: HGSI ) today announced that the ...e-saving potential of its human,monoclonal antibod... that a,single dose of ABthrax, administered witho...
Other Medicine Technology:Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program 2Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program 3Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program 4Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program 5New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies 2New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies 3New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies 4New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies 5New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies 6New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies 7
(Date:11/27/2009).... 27 Shamir Optical Indu... provider of innovative products and technology to...its board of directors had declared a dividend dis... (approximately NIS 37.62 million based on the Nov...r approximately US$ 0.609 (approximately NIS 2.3 b...
(Date:11/27/2009)...vehicles may reduce future disease burden, researc...News) -- Encouraging city dwellers to walk and bic...r public health benefits than increased used of lo..., The study compared the projected health effec...narios for London, England, and Delhi, India: bus...
(Date:11/27/2009)...ov. 27 Allrecipes.com , the wor...ng traffic numbers, with more than 2.8 million vis...ar picture of what was served on the biggest food ... in 2009 weighed in at 2,225 calories per serving,...rding to the Allrecipes site, Sweet Potato Pie I ...
(Date:11/27/2009)...e bilingual coloring books designed for children a...unity to educate - inform parents and children ali...Dinosuars to ABC,S and a host of other topics. , ...vember 27, 2009 -- Today’s children have eno... any hour of the day, but one of the oldest and si...
(Date:11/27/2009)...teractive anatomy education apps from Modality and...ciences learning opportunities for iPhone and iPod...s) November 27, 2009 -- Modality, Inc. and Lippi...Wolters Kluwer Health, today announced the availab...pp Store. Clemente’s Anatomy, Rohen’s ...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5
...at the U.S. Department of Energy,s Brookhaven Nati...in level of receptors for dopamine, a pleasure-rel...cent in rats trained to self-administer it. Earlie...ve useful in treating addiction, according to the ...
...16 The Blackstone,Group has today informed us tha... Gerresheimer AG, held by BCP Murano II S.a.r.l. w...tion, led by Credit Suisse, 7.8 million,shares wil...07. Dr. Axel Herberg, CEO of Gerresheimer AG: "Bla...
...ay is National Skin Cancer,Awareness Month. TOPEX,...his disease with a low energy or superficial x-ray...ent procedure. This new system provides,an alterna...sitive structures in the head and neck regions -- ...
...omen with breast cancer have worse disease outcome... first time with more advanced disease, two scient...e (EBCC-6) today (Wednesday 16 April). , Dr. E...howed that women who had a body mass index (BMI) o...
...O2 Plastics, Inc.,(OTC Bulletin Board: ECOO), the ...e way plastics are recycled, today reported its 20.... The Company reported revenues of,$4.3 million fo... $32.6 million in 2007 versus $20.8 million for th...
...ers at the Duke School of Medicine apparently have...so much, and it may be a mechanism that could lead... a graduate student in Assistant Professor Jeffrey...ogrammed cell death. They make use of a protein ca...
Other Medicine News:Health News:Gene therapy reduces cocaine use in rats 2Health News:An Alternative to Surgery for Treating Skin Cancer 2Health News:An Alternative to Surgery for Treating Skin Cancer 3Health News:Obese women disadvantaged in both breast cancer treatment and diagnosis 2Health News:Obese women disadvantaged in both breast cancer treatment and diagnosis 3Health News:ECO2 Plastics, Inc. Reports 2007 Year End Financial Results, Announces FDA Filing and Provides Outlook for 2008 2Health News:ECO2 Plastics, Inc. Reports 2007 Year End Financial Results, Announces FDA Filing and Provides Outlook for 2008 3Health News:A potential sugar fix for tumors 2
Lasik Irrigator - 4 ports
Lasik Cannula - Rosen
Anterior Chamber Maintainer
Sub-Tenon's Cannula
Medicine Products: